MY129726A - Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics - Google Patents
Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcoticsInfo
- Publication number
- MY129726A MY129726A MYPI20022245A MYPI20022245A MY129726A MY 129726 A MY129726 A MY 129726A MY PI20022245 A MYPI20022245 A MY PI20022245A MY PI20022245 A MYPI20022245 A MY PI20022245A MY 129726 A MY129726 A MY 129726A
- Authority
- MY
- Malaysia
- Prior art keywords
- active ingredient
- desoxypeganine
- acamprosate
- galanthamine
- narcotics
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title 1
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 title 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title 1
- 229960004047 acamprosate Drugs 0.000 title 1
- 229960003980 galantamine Drugs 0.000 title 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 title 1
- 229960004640 memantine Drugs 0.000 title 1
- 239000004081 narcotic agent Substances 0.000 title 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129265A DE10129265A1 (de) | 2001-06-18 | 2001-06-18 | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY129726A true MY129726A (en) | 2007-04-30 |
Family
ID=7688529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20022245A MY129726A (en) | 2001-06-18 | 2002-06-17 | Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040192683A1 (enExample) |
| EP (1) | EP1397138B1 (enExample) |
| JP (1) | JP2005500298A (enExample) |
| KR (1) | KR20040010744A (enExample) |
| CN (1) | CN1527711A (enExample) |
| AR (1) | AR034493A1 (enExample) |
| AT (1) | ATE286397T1 (enExample) |
| AU (1) | AU2002323873B2 (enExample) |
| BR (1) | BR0211008A (enExample) |
| CA (1) | CA2450787C (enExample) |
| CZ (1) | CZ299951B6 (enExample) |
| DE (2) | DE10129265A1 (enExample) |
| EA (1) | EA006647B1 (enExample) |
| ES (1) | ES2236551T3 (enExample) |
| HU (1) | HUP0400865A3 (enExample) |
| IL (2) | IL159345A0 (enExample) |
| MX (1) | MXPA03011825A (enExample) |
| MY (1) | MY129726A (enExample) |
| NO (1) | NO20035458D0 (enExample) |
| NZ (1) | NZ529944A (enExample) |
| PL (1) | PL367207A1 (enExample) |
| PT (1) | PT1397138E (enExample) |
| SK (1) | SK287180B6 (enExample) |
| TW (1) | TWI325320B (enExample) |
| UA (1) | UA76753C2 (enExample) |
| WO (1) | WO2002102388A2 (enExample) |
| ZA (1) | ZA200309232B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10134038A1 (de) * | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| DE10318714B4 (de) * | 2003-04-25 | 2006-03-23 | Hf Arzneimittelforschung Gmbh | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
| DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
| DE102004048927A1 (de) * | 2004-10-06 | 2006-04-20 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| AU2006244297A1 (en) | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of CNS disorders |
| WO2006124584A2 (en) * | 2005-05-13 | 2006-11-23 | Alza Corporation | Multilayer drug delivery system with barrier against reservoir material flow |
| DE602006017719D1 (de) | 2005-09-01 | 2010-12-02 | Mitsubishi Chem Corp | Verfahren zur wärmebehandlung von polyesterteilchen und verfahren zur mehrstufigen festphasenpolykondensation von polyesterteilchen |
| WO2007035941A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal galantamine delivery system |
| US9463172B2 (en) | 2009-02-12 | 2016-10-11 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| EP3132793A1 (en) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| US9000046B2 (en) | 2010-09-28 | 2015-04-07 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
| RS65198B1 (sr) * | 2010-12-03 | 2024-03-29 | Nalpropion Pharmaceuticals Llc | Povećana biodostupnost leka u terapiji naltreksonom |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
| TWI678202B (zh) * | 2016-12-14 | 2019-12-01 | 陸汝斌 | 組合物用於製備治療酒癮或酒精濫用之藥物的用途 |
| WO2019040748A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE |
| BG67408B1 (bg) * | 2019-04-12 | 2022-01-17 | Софарма Ад | Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
| US3742951A (en) * | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
| US4031894A (en) * | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
| DE3315272C2 (de) * | 1983-04-27 | 1986-03-27 | Lohmann Gmbh & Co Kg, 5450 Neuwied | Pharmazeutisches Produkt und Verfahren zu seiner Herstellung |
| DE3843239C1 (enExample) * | 1988-12-22 | 1990-02-22 | Lohmann Therapie Syst Lts | |
| EP0424179A3 (en) * | 1989-10-20 | 1991-12-27 | John William Olney | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration |
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| CZ295528B6 (cs) * | 1994-10-21 | 2005-08-17 | Sanochemia Pharmazeutika Ag | Způsob výroby derivátů 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinu |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9514821D0 (en) * | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| EP0945133A1 (en) * | 1998-03-26 | 1999-09-29 | Lipha | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| WO1999054280A1 (en) * | 1998-04-17 | 1999-10-28 | Kenneth Curry | Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation |
| DE19906978B4 (de) * | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit |
| DE19906979B4 (de) * | 1999-02-19 | 2004-07-08 | Lts Lohmann Therapie-Systeme Ag | Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit |
| DE19906974C2 (de) * | 1999-02-19 | 2003-10-09 | Lohmann Therapie Syst Lts | Verwendung von Desoxypeganin zur Behandlung des Alkoholismus |
-
2001
- 2001-06-18 DE DE10129265A patent/DE10129265A1/de not_active Withdrawn
-
2002
- 2002-06-14 AR ARP020102244A patent/AR034493A1/es unknown
- 2002-06-15 PL PL02367207A patent/PL367207A1/xx unknown
- 2002-06-15 JP JP2003504974A patent/JP2005500298A/ja active Pending
- 2002-06-15 SK SK1565-2003A patent/SK287180B6/sk not_active IP Right Cessation
- 2002-06-15 EA EA200400041A patent/EA006647B1/ru not_active IP Right Cessation
- 2002-06-15 US US10/480,287 patent/US20040192683A1/en not_active Abandoned
- 2002-06-15 WO PCT/EP2002/006630 patent/WO2002102388A2/de not_active Ceased
- 2002-06-15 CZ CZ20033390A patent/CZ299951B6/cs not_active IP Right Cessation
- 2002-06-15 ES ES02754688T patent/ES2236551T3/es not_active Expired - Lifetime
- 2002-06-15 NZ NZ529944A patent/NZ529944A/en unknown
- 2002-06-15 AT AT02754688T patent/ATE286397T1/de not_active IP Right Cessation
- 2002-06-15 IL IL15934502A patent/IL159345A0/xx active IP Right Grant
- 2002-06-15 HU HU0400865A patent/HUP0400865A3/hu unknown
- 2002-06-15 KR KR10-2003-7016570A patent/KR20040010744A/ko not_active Ceased
- 2002-06-15 UA UA20031211802A patent/UA76753C2/uk unknown
- 2002-06-15 EP EP02754688A patent/EP1397138B1/de not_active Expired - Lifetime
- 2002-06-15 CN CNA028110196A patent/CN1527711A/zh active Pending
- 2002-06-15 PT PT02754688T patent/PT1397138E/pt unknown
- 2002-06-15 AU AU2002323873A patent/AU2002323873B2/en not_active Ceased
- 2002-06-15 MX MXPA03011825A patent/MXPA03011825A/es active IP Right Grant
- 2002-06-15 CA CA002450787A patent/CA2450787C/en not_active Expired - Fee Related
- 2002-06-15 BR BR0211008-3A patent/BR0211008A/pt not_active Application Discontinuation
- 2002-06-15 DE DE50201958T patent/DE50201958D1/de not_active Expired - Lifetime
- 2002-06-17 MY MYPI20022245A patent/MY129726A/en unknown
- 2002-06-17 TW TW091113176A patent/TWI325320B/zh not_active IP Right Cessation
-
2003
- 2003-11-27 ZA ZA200309232A patent/ZA200309232B/xx unknown
- 2003-12-08 NO NO20035458A patent/NO20035458D0/no not_active Application Discontinuation
- 2003-12-11 IL IL159345A patent/IL159345A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY129726A (en) | Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics | |
| MX9602683A (es) | Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas. | |
| AP9801392A0 (en) | Concentrated antibody preparation. | |
| CA2391808A1 (en) | Method for treatment of symptoms of central nervous system disorders | |
| WO2003030823A3 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| HUT70705A (en) | Device for vaporizing an active substance, for example insecticide or airfresheuer | |
| AU2002323873A1 (en) | Active ingredient combination of E.G. galanthamine or deoxypeganine and E.G. acamprosate or memantine for treating an addiction such as alcoholism | |
| WO1999002143A3 (en) | Medicament comprising adenosine | |
| EP0861663A3 (en) | Osteoclastgenic inhibitory agent comprising interleukin-18 | |
| BR9608255A (pt) | Sistema terapéutico transdérmico (stt) para a administração de testosterona | |
| JO2017B1 (en) | Pharmaceutical formula for infectious residence | |
| GT199900062A (es) | Preparados efervescentes. | |
| BR9810433A (pt) | Composições anti-helmìnticas | |
| EP1273301A3 (en) | Pharmaceutical preparations based on active ingredients susceptible to illict administration | |
| ZA963744B (en) | Topical aciclovir preparation | |
| EP1018336A4 (en) | carcinostatic | |
| CA2452432A1 (en) | Active ingredient combination for the pharmacological therapy of nicotine dependence | |
| IL139303A0 (en) | Treatment of arthritis and other similar conditions | |
| MX9603342A (es) | Piranos-4h-sustituidos. | |
| MXPA04000008A (es) | Carbamatos de 2-heterociclic-1,2-etanodioles. | |
| PT1244498E (pt) | Combinacao de trimebutina com um analgesico opiode | |
| WO1999029319A3 (en) | Chemical compounds for use as anxiolytic agents and a method for the identification of anxiolytic compounds | |
| ES2141044A1 (es) | Terapia con oxibutinina. | |
| UA36385A (uk) | Спосіб лікування генералізованого пародонтиту | |
| UA32122A (uk) | Спосіб профілактики розвитку еклампсій |